Coherus Oncology, Inc. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Coherus announced interim Phase 1b data from TREGCHECK program for tagmokitug (CCR8 antibody) combined with toripalimab in solid tumors. In first-line ESCC (8 evaluable patients as of Oct 14, 2026), confirmed ORR was 75% overall and 100% in PD-L1-positive patients; post-cutoff rate reached 89% (8/9). Second-line ESCC (8 evaluable from 17 safety-evaluable) showed 16.7% cORR at 700mg dose with 5.5-month median PFS vs. 3.4-month benchmark. Safety was manageable across 120+ patients with no new signals; no Grade 5 TRAEs reported. Company will expand ESCC enrollment and advance combinations with T-cell engagers.
Why this rating
Clinical proof-of-concept for lead pipeline asset in commercially relevant indication, strong response rates vs. standard-of-care, supports pivotal advancement. Relative to $81.9M market cap, successful pipeline validation is material; however, Phase 1b data carry inherent execution risk.
Price action (we called it positive)
before filing · preread $1.03 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.